Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cypress Bioscience, Inc.
San Diego, California, United Statescypress.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cypress Bioscience developed two FDA-approved products—Prosorba™ for rheumatoid arthritis and Savella® (milnacipran HCl) for fibromyalgia. Its pipeline included CNS-focused assets such as CYP‑1020 for cognitive impairment in schizophrenia, Staccato® nicotine for smoking cessation, and intranasal carbetocin for autism. After its acquisition by Ramius LLC and Royalty Pharma in 2010–2011, most development programs were discontinued or shelved
- Therapeutic areas
- PulmonologyImmunologyPsychiatryRheumatologyNeurology
- Modalities
- Small moleculesMedical devices (e.g., Prosorba™)
- Industry
- Biotech
02
Partnerships
Royalty Pharma acquired rights to Savella royalties through this transaction. No other major partnerships noted at the time of acquisition.
Beyond the preview
Go deeper on Cypress Bioscience, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cypress Bioscience, Inc..